Grant: Collaborative Health Research Projects (NSERC partnered)
McMaster University
$261,250.00
Development of Molecularly Targeted Ultrasound Contrast Agents for Prostate Cancer Imaging using Bioorthogonal Chemistry
FY 2015-16
Summary
Current imaging and biopsy methods for the detection of prostate cancer have major limitations that impact patient outcomes and can lead to unnecessary treatments. These include the use of ineffective therapies, or unnecessary and life-altering side effects being experienced by patients, resulting in added and unnecessary expense and burden to the healthcare system.
The aim of the proposed study is to overcome these limitations by using ultrasound imaging, together with a new generation of targeted contrast agents that bind to prostate cancer cells, but not to normal tissue. The microbubble contrast agents utilize a new targeting technology that allows them to collect only in aggressive tumors, resulting in an enhanced ultrasound signal. With this approach, it will be possible to properly identify those patients that need immediate and more aggressive treatment, from those that can opt for active surveillance. It will also create a tool to help better guide biopsies, in order to minimize sampling errors and the need to repeat procedures, which at present happen too frequently. The availability of ultrasound technology in most cancer centers makes this approach both feasible and highly useful for detection and monitoring of prostate cancer.
The project will be accomplished through collaboration between a chemistry group at McMaster University and an ultrasound imaging group at Sunnybrook Hospital. Students from science and health science fields will work in teams to carry out the specific aims. The proposal is supported by strong preliminary research and the active participation of a Canadian ultrasound imaging company and a national centre of excellence, whose expertise ensure that the new technologies can quickly move from the laboratory to the clinic, and ultimately to the market. The results of this project could bring a paradigm shift in how prostate cancer patients are diagnosed, and at the same time reduce unnecessary treatments and improving outcomes.
Department
Program
Collaborative Health Research Projects (NSERC partnered)
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
336372
Name
Valliant John F
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Natural Sciences and Engineering Research Council of Canada (NSERC)
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Collaborative Health Research Projects - NSERC Partnered
Projecttitle
Development of Molecularly Targeted Ultrasound Contrast Agents for Prostate Cancer Imaging using Bioorthogonal Chemistry
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$261,250
Cihrequipment2
$0
Programname2
Collaborative Health Research Projects (NSERC partnered)
Keyworddelim
Bioorthogonal Chemistry; Microbubbles; Molecular Imaging; Prostate Cancer; Prostate Specific Membrane Antigen; Ultrasound
Abstract
Current imaging and biopsy methods for the detection of prostate cancer have major limitations that impact patient outcomes and can lead to unnecessary treatments. These include the use of ineffective therapies, or unnecessary and life-altering side effects being experienced by patients, resulting in added and unnecessary expense and burden to the healthcare system.
The aim of the proposed study is to overcome these limitations by using ultrasound imaging, together with a new generation of targeted contrast agents that bind to prostate cancer cells, but not to normal tissue. The microbubble contrast agents utilize a new targeting technology that allows them to collect only in aggressive tumors, resulting in an enhanced ultrasound signal. With this approach, it will be possible to properly identify those patients that need immediate and more aggressive treatment, from those that can opt for active surveillance. It will also create a tool to help better guide biopsies, in order to minimize sampling errors and the need to repeat procedures, which at present happen too frequently. The availability of ultrasound technology in most cancer centers makes this approach both feasible and highly useful for detection and monitoring of prostate cancer.
The project will be accomplished through collaboration between a chemistry group at McMaster University and an ultrasound imaging group at Sunnybrook Hospital. Students from science and health science fields will work in teams to carry out the specific aims. The proposal is supported by strong preliminary research and the active participation of a Canadian ultrasound imaging company and a national centre of excellence, whose expertise ensure that the new technologies can quickly move from the laboratory to the clinic, and ultimately to the market. The results of this project could bring a paradigm shift in how prostate cancer patients are diagnosed, and at the same time reduce unnecessary treatments and improving outcomes.
Competitiondate
201510
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Valliant, John F; Foster, F. Stuart
Approvedterm
3 ans 0 mois
Cihrcontribution2
Major Initiatives #2~ $261,250~ $0~